Metabolic / Weight Management
CagriSema
Cagrilintide + semaglutide combination. REDEFINE 1: 22.7% mean body weight loss at 68 weeks.
Evidence: 3 articles
Goals: 1
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Level
Clinical Trial - Human
3 studies published
Pharmacology
Molecular Weight
~4,100 Da (cagrilintide component)
Half-Life
~164 hours (cagrilintide); ~165 hours (semaglutide) — enabling once-weekly dosing
Bioavailability
Subcutaneous injection; high systemic bioavailability via acylation-driven albumin binding